The Theranos Fraud: A Case Study in Corporate Governance Failure

At its peak, Theranos was valued at around $9 billion, and its founder Elizabeth Holmes was celebrated as the youngest self-made female billionaire in the United States. The company claimed it had reinvented blood testing — running hundreds of tests from a single finger-prick of blood, using proprietary devices it called "Edison" machines. Almost none of it worked as claimed. In January 2022, a federal jury convicted Holmes of fraud, and in November 2022 she was sentenced to just over 11 years in prison. Theranos is now one of the most-cited corporate governance failures in modern business history.

The promise

Founded by Holmes in 2003 after she dropped out of Stanford, Theranos promised to disrupt an unglamorous but enormous market: diagnostic blood testing. Instead of drawing multiple vials of blood for a lab panel, Theranos said its technology could run over 200 different tests from a single drop taken via finger-prick, cheaply and quickly, in-house at pharmacies. The pitch attracted an unusually prominent board — former US secretaries of state, senators, and military generals — and raised more than $700 million from investors, many of whom had little background in medical diagnostics and, crucially, were never shown independent proof the technology worked.

The reality

In 2015, investigative reporting (most notably by the Wall Street Journal's John Carreyrou) revealed that Theranos's proprietary Edison machines could reliably run only a small fraction of the tests the company claimed, and that Theranos was secretly running the vast majority of patient samples on standard commercial lab equipment from other manufacturers — the exact technology it claimed to have replaced. Internal whistleblowers described a culture where employees who questioned the technology's accuracy were pushed out or intimidated, and where test results sent to real patients and their doctors were, in a meaningful number of cases, simply wrong.

The trial and verdict

US regulators voided two years of Theranos test results in 2016. The company was eventually dissolved in 2018. Holmes and her former deputy (and romantic partner) Ramesh "Sunny" Balwani were criminally charged with wire fraud and conspiracy for deceiving investors, doctors and patients. Holmes was convicted in January 2022 on four of twelve counts — specifically the counts relating to defrauding investors, not patients — and sentenced in November 2022 to 11 years and 3 months in prison, later reporting to custody in 2023. Balwani was convicted on all counts against him and received a longer sentence.

Why this matters for finance professionals

Theranos is now a standard case study in corporate governance and audit ethics precisely because so much of what went wrong was avoidable with basic diligence. Investors wrote large cheques without independent verification of the core technology. The board lacked anyone with relevant medical or scientific expertise to properly challenge management's claims. And because Theranos was privately held, it wasn't subject to the same disclosure and audit requirements as a public company — a gap that let the fraud run for years before it surfaced. For anyone studying professional ethics, audit, or corporate governance, the case is a reminder that financial statements and glossy pitch decks are not the same as verified facts, and that "who's on the board" matters less than "what can the board actually assess."

Frequently asked questions

Did any Theranos patients get hurt by false test results?

Yes — reporting and court testimony described patients receiving inaccurate results for conditions including pregnancy complications and cancer markers, though Holmes's criminal conviction centred specifically on defrauding investors rather than patients.

How much money did Theranos raise from investors?

More than $700 million over its lifetime, from a mix of venture investors, private wealth, and some high-profile individual backers — nearly all of it lost when the company collapsed.

Is Theranos similar to the Wirecard scandal?

Both involved sustained, deliberate deception of investors and a board that failed to catch it — but where Wirecard fabricated financial statements at a public, audited company, Theranos misrepresented its technology at a private company that faced far less external scrutiny.

Professional ethics and corporate governance are core to Learnsignal's ACCA Strategic Business Leader course, which uses cases like Theranos to test how candidates would actually respond under pressure to compromise.

How the fraud stayed hidden for so long

Part of what makes Theranos instructive is how ordinary the mechanics of the deception were. There was no exotic accounting or offshore structure involved — Holmes and Balwani simply restricted access to the company's labs and technology, citing trade-secret protection, so that outside experts, journalists, and even some employees were kept from seeing how results were actually produced. Investors were shown staged demonstrations rather than given independent access to validate the claims. That pattern — using confidentiality as a shield against scrutiny rather than a genuine protection of intellectual property — is now something auditors and investors are trained specifically to probe for when a company's growth story looks too clean.

Related Case Studies

• WeWork: How a $47 Billion Valuation Collapsed
• The Allen Stanford Scandal: A $7 Billion Ponzi Scheme Case Study
• The Bre-X Scandal: A Salted Gold Mine Fraud Case Study
• Accounting Scandals – List and Overview